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Abstract
Candida

causes

superficial

infections

in

healthy

individuals;

however

in

the

immunocompromised host Candida can cause invasive, systemic infections and is a
significant cause of morbidity and mortality. This is not due to a more virulent phenotype but
to a weakened immune system unable to fight this oppertunistic pathogen. The
immunocompromised population is ever increasing, due to medical advancements and more
aggressive treatments, and hence is the need for epidemiological data of these potentially life
tlireatening infections. The aim of this study was to provide an epidemiological snapshot, of
Candida infections from the immunoeompromised population in Cork hospitals. Surveillance
programmes from the U.S. and globally, have demonstrated a changing epidemiological trend,
which suggests an increase in the prevalence of r\on-albicans Candida (NAC), in particular C.
glahrata and a decrease in C. albicans infections. This potential epidemiological shift could
have strong implications, due to the greater difficulties in the treatment of infections with
NAC, particularly those displaying greater resistance patterns. The mortality associated with
certain NAC, such as C. krusei, is also greater than that with C. albicans infections. This may
put increasing pressure on diagnostic tests for the correct strain identification, which presently
are lacking and based on phenotypic rather than molecular applications.
Twenty-five isolates were characterised by strain identification. Each Candida strain was
typed by a sugar utilisation method (API Kit), used routinely in hospital laboratories. These
results were compared to those generated by a molecular method, which amplifies the
domains 1 and 2 (D1/D2) of the large subuit 26S rDNA gene, in which nucleotide variations
within this region ean be used to diffrenciate strains. The sensitivity of the API kit could then
be determined, by comparison to the sequencing results generated, as the reference for the
correct strain identification. The identification results matched in 24/25 cases, indicating the
API Kit is a reliable and sensitive (96%) tool. The one discrepancy was identified as C.
famata by the API method and C. tropicalis by sequencing, which is the DNA blueprint of
the organism, and therefore the definitive result. C albicans accounted for 68% (17/25) of
isolates, followed by C. parapsilosis 16% (4/25), and one strain each of C. glabrata, C.
lusitaniae, C. tropicalis, and C dubliniensis each representing 4% of the total isolates. This
data indicates that C. albicans is the dominant strain, but that there are a variety of NAC

strains also present in Cork hospitals. C. parapsilosis rather than C. glabrata was the second
most dominant strain which differs to studies in the U.S. and globally which suggests the
emergence of C. glabrata. The presence of C. parapsilosis at 16% is worrying and may
suggest hyper alimentation, breaches in catheter control and the need for improvement in
infection control practices.
Fluconazole is the most frequently used antifungal agent, administered prophylactically and in
the treatment of candidaemia, due to its favourable tolerability and effectiveness. However, it
is not effective against C. krusei infection which is intrinsically resistant to fluconazole, C.
glabrata which has decreased susceptibility and C. albicans has also developed resistance to
this common antifungal agent. In this study, fluconazole susceptibility profiles were assigned
to each of the twenty-five strains. All were susceptible to fluconazole with a minimum
inhibitory concentration (MIC) of < 8ug/ml. The average MIC of the NAC strains were 6.5
fold more resistant compared to C. albicans isolates. A higher level of resistance among NAC
is consistent with similar studies. A tenfold difference in MIC was also noted between some
isolates, and the possible role of efflux gene over expression contribution to resistance,
remains to be elueidated.
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1. Introduction
Candida is a normal commensal organism of the skin, gastrointestinal and genitourinary traet.
There are more than 200 species, most of which belong to the normal flora, with only 10% of
these causing infections (Eggimann P. et al, 2003). Superficial infections include Candida
vulvovaginitis, which is easily treated and not life threatening. However, Candida can also
cause invasive fungal infections among the immunocompromised and critically ill, which are
associated with increased morbidity and mortality in these patients (Eggimann P. et al, 2003).
Studies have reported a crude mortality rate of between 40-75% associated with nosocomial
candidaemia (Edmond M.B. et al, 1999) and attributed mortality rates of 49% (Gudlaugsson
O.S. et al, 2003). It is the fourth leading cause of nosoeomial bloodstream infection (BSI)
worldwide (Tumbarello M. et al, 2007) and the single most important cause of opportunistic
mycoses worldwide (Pfaller M. A. Et al, 2007). These life threatening infections have an
unacceptably high oceurrence and are a significant public health burden (Pfaller M.A. et al,
2007).

The HIV epidemic highlighted the significance of opportunistic infections, with 80% of
patients having developed mucosal candidiasis prior to the availability of highly active
antiretroviral therapy (HAART) which significantly reduced fungal infeetions (Warnock
D.W., 2007). However, these infections still remains a significant cause of death in the
developing world, in the absence of HAART therapy (Clark T.A. et al, 2002). Medical
advancements have meant improved survival for life threatening infections, but a resulting
increased size in the population at risk, for systemic Candida infections. Treatments including
antineoplastic and immunosuppressive agents, broad spectrum antibiotics, prosthetic devices,
grafts and more aggressive surgery are associated with an increased risk (Enoch D.A. et al,
2006). In a study by the European Confederation of Medical Microbiology, (E.C.M.M.)
involving 2089 patients from seven countries, the underlying pathology of patients with
candidaemia was surgery (48%), intensive care (40%), solid tumour (23%), steroids (17%),
haematological malignancy (12%), premature birth (6%), HIV infection (3%) and bums (1%)
(Tortorano et al, 2006). Candida BSIs can be endogenous with colonisation of the mucous
membranes suggested as a prerequisite to deep seated infection, or exogenously acquired e.g.
via catheters (Tortorano A. Et al, 2006). However endogenous and exogenous colonisations
can also co exist (Eggiman et al, 2003).

Exogenous source

Endogenous source

Figure 1: The colonisation, adhesion, invasion and dissemination of exogenous and
endogenous sources of Candida causing Candidaemia. (Adapted from Eggimann et al, 2003).

2. International Epidemiological Trends

International epidemiological studies of the prevalence of Candida species, vary
geographically. Rates of candidaemia are highest in the U.S. (1.5 per 10,000 patient-days),
compared to surveys in European countries (0.31-0.44 per 10,000 hospital days (Tortorano A.
Et al, 2006). However, rates of candidaemia vary considerably in the U.S. also, with 6 cases
per 100,000/yr in Iowa compared to a high of 24 per I00,000/yr in Baltimore (Pfaller et al,
2007). 90% of invasive candidaemia are attributed to five species; C. albicans, C. glabrata, C.
parapsilosis, C. tropicalis, and C. krusei, although the list of clinical species isolated
continues to grow (Pfaller M.A. et al, 2007). The E.C.M.M. study highlighted the severity of
candidaemia in patients, with highest crude mortality rates associated with C. krusei, C.
glabrata and C. tropicalis at 55.3, 45 and 41.4% compared to C. albicans and C. parapsilosis
at 38.5 and 25.9 % respectively (Tortorano A. Et al, 2006).

2.1 C. albicans
In epidemiological surveillance programmes the dominant species causing invasive
candidiasis (IC) worldwide is C. albicans, although its prevalence varies from a high of 63%
in Europe, to 52% in U.S.A. and a low of 34% in Brazil (Eggiman P. et al, 2003).
Historically, C. albicans accounted for 70-80% of cases with non-albicans Candida (NAC)
strains occurring less frequently, however several studies have suggested an increase in NAC
and a decrease in the prevalence of C. albicans (Fidel, P.L. et al, 1999, Krcmery V. Et al,
2002, Syndmen D.R. et al, 2003).
Table 1: Species distribution of Candida from cases of IC (Adapted from Pfaller et al, 2007).

Species

% of total no. of cases*

1997-1998

1999

2000

2001

2002

2003

C. albicans

73.3

69.8

68.1

65.4

61.4

62.3

C. glabrata

11.0

9.7

9.5

11.1

10.7

12.0

C. tropicalis

4.6

5.3

7.2

7.5

7.4

7.5

C. parapsilosis

4.2

4.9

5.6

6.9

6.6

7.3

C. krusei

1.7

2.2

3.2

2.5

2.6

2.7

C. guilliermondii

0.5

0.8

0.8

07

10

08

C. lusitaniae

0.5

0.5

0.5

0.6

0.5

0.6

C. kefyr

0.2

0.4

0.5

0.4

0.4

0.5

C. nigosa

0.03

0.03

0.2

0.7

0.6

0.4

C. famata

0.08

0.2

0.5

0.2

0.4

0.3

C. inconspicua

0.08

0.1

0.2

0.3

C. norvegensis

0.08

0.1

0.07

0.1

C. dubliniensis

0.01

0.08

0.1

0.05

C. lipolytica

0.06

0.06

0.06

0.08

C. zeylanoides

0.03

0.08

0.02

0.04

0.06

0.05

0.04

C. pelliculosa
Candida spp."^
Total no. of cases

3.9

6.0

3.7

3.3

7.9

4.9

22,533

20,998

11,698

21,804

24,680

33,002

Table 1 shows a consistent decreasing trend in C. albicans and increasing prevalence in C
glabrata, C. tropicalis, C. parapsilosis, C. krusei and also among the more rare Candida
species, data which was compiled from 39 countries by the Artemis Disk Surveillance
Program. This epidemiological trend is a concern, as NAC strains are associated with
treatment difficulties and increased mortality, particularly among C. glabrata and C. krusei,
due to their increased resistance to antifungal agents.

Krcmery et al. describe an increase from 10-40% to 35-60% of candidaemia, attributed to
NAC in just two decades (Krcmery et al, 2002). The increase in use of fluconazole and in
particular its use prophylactically, has been identified as a risk factor in contributing to the
increase in NAC (Playford, E.G.et al, 2008). However, several studies have indicated no
significant increase in the incidence of NAC, due to fluconazole prophylaxis and have
highlighted its benefits in reducing candidaemia associated mortality (Girao E. et al, 2008,
Boktar M.R. et al, 2004, Healy C.M. et al, 2008).

Table 2: Distribution of Different Candida Species Among Patients With Haematological
Malignancies and Solid Tumours (Adapted from Hachem et al, 2008).
No. of patients (Vo)
Candida species

C. albicans
C. glabrata
C. krusei
C. parapsilosis
C. tropicalis
C. guilliermondii
C. lusitaniae
Mixed Candida species

HM,n = 281ST, n = 354^

38 (14)
86(31)
68 (24)
39(14)
27(10)
4(1)
3(1)
16(6)

161 (45)
64(18)
6(2)
71 (20)
30(9)
2(1)
3(1)
17(5)

<.001
<.001
<001
.045
.620
.410
.990
.620

HIVl indicates patients with hematologic malignancies;
ST, patients with solid tumors.

Some studies suggest that NAC occurs more frequently in cancer patients, and in particular
haematological malignancies and bone marrow transplant recipients (40-70%), followed by
ICU and surgical patients (35-55%), children (1-35%) and HIV positive individuals (0-33%)
(Krcmery V. et al, 2002). In the E.C.M.M. study, the majority of NAC strains were isolated
from patients with haematological malignancies (Tortorano A.M. et al, 2004), which was also

the case in the study by Hachem et al. shown in Table 2. Different patient populations and risk
factors are likely to be associated with particular Candida species as indicated in Table 3.

Table 3: Independent Risk Factors associated with Candida species (Adapted from Hachem et
al, 2008).
Candida species Independent risk factor

OR 95% Cl

C. albicans

1.560 1.200-2.440

No neutropenia

No fluconazole prophylaxis 3.3302.040-5.560
Presence of solid tumor

2.5001.540-4.000

C. tropicalis

Neutropenia

2.325 1.287-4.202

C. glabrata

Fluconazole prophylaxis

2.041 1.361-3.060

C. krusei

Fluconazole prophylaxis

5.260 2.922-9.468

Neutropenia

5.3782.696-10.727

C. parapsilosis Catheter-related candidaemia2.470 1.587-3.845

2.2 C. glabrata

C. glabrata was formally classified in the genus Torulopsis, prior to the naming of the genus
Candida (Fidel, P.L. et al, 1999). It was then decided that the ability to produce pseudohypha,
was not a distinguishing feature for Candida and the non pseudohyphae producing T. glabrata
joined the Candida genus (Fidel P.L. et al, 1999). Many studies suggest that C. glabrata is the
second most dominant strain causing candidaemia in the U.S. (Halleh R.A. et al, 2004). Data
from the Sentry Program support this, with C. glabrata present in 21% of isolates in the U.S.
(Table 4). The Sentry Antimicrobial Surveillance programme, suggests that the prevalence of
C. glabrata particularly in the U.S., may be due to extensive utilisation of fluconazole at
relatively low doses (<400 mg/day) which perhaps encouraged its selection (Pfaller M.A. et
al, 2000).
Interestingly, in data compiled by the Sentry Program from 23 centres in Europe, C.
parapsilosis was the second most dominant strain (19%), compared to C. glabrata (10%)
shown in Table 4. In contrast, the ECMM report that C. glabrata is Europe’s second most
dominant strain (13.6%), followed closely by C. parapsilosis (13.3%) shown in Table 5.
These differences may be due to a recent epidemiological shift with an increase in the

prevalence of C. glabrata from period 1997-1999 (Sentry programme) to 2004 (ECMM
Study). This is just speculative; the ECMM study had however a much greater case load of
2089, compared to 302 cases in the Sentry program. The E.C.M.M. survey reported C.

glabrata as the second most common species isolated in France, Germany, Austria, Sweden
and the U.K. apart from in Italy and Spain where it ranked 3*^^ and 4^^ (Tortorano et al, 2006).
A large study in Europe, also reported C. glabrata as the second most prevalent disease
causing strain, (10%) followed closely by C. parapsilosis (9%) respectively, of 19 studies
involving 5194 strains (Eggiman P. et al, 2003).
A large increase in the prevalence of C. glabrata and C. krusei was reported at the Anderson
Cancer Centre in the U.S. (Hachem et al, 2008) however only small increases were noted
globally by the Artemis Surveillance Program (Pfaller M. et al, 2005). This may be due to
differences in patient populations, between a large cancer specialist centre versus mixed
tertiary general care hospitals, and geographical differences among the U.S. and globally.

Table 4: Species distribution of Candida bloodstream isolates: SENTRY Program, 19971999. (Adapted from Pfaller et al, 2001).
% Isolates by geographic area"

Species

U.S. (« = 589)

Canada {n= 161)

Latin America {n = 132)

Europe {n = 302)

45

58

C. albicans

55

60

C. glabrata

2P

12

6

10

11

16

25’-

19’-

^.parapsilosis
C. tropicalis

9

6

16*^

7

C. kneei

2

2

1

1

Candida spp.

2

4

7

5

' n, no. tested. U.S., United States.
’ P ^ 0.01 compared to prevalence in other geographic areas.

P ^ 0.001 compared to prevalence in the United States

Table 5: Species distribution of Candida bloodstream infection by the ECMM. (Adapted
from Tortorano et al, 2006).

Species

No. (%) of

Range“

episodes
C. albicans

1178 (56.4)

42.767.0

C. glabrata

284 (13.6)

8.3-16.1

C. parapsilosis

278 (13.3)

6.9-30.0

C. tropica Us

152 (7.2)

2.1-10.0

C. krusei

40(1.9)

0-3.1

C. guilliermondii

30(1.4)

0-2.1

C. lusitaniae

15 (0.7)

0-2.0

C. kefyr

10 (0.5)

0-1.6

C. pelliculosa

9 (0.4)

0-1.2

C.famata

7 (0.3)

0-1.4

C. dubliniensis

6(0.3)

0-1.8

C. lipolytica

6(0.3)

0-0.7

C. norvegensis

5 (0.2)

0-0.5

C. inconspicua

4 (0.2)

0-0.5

C. utilis

2(0.1)

0-0.2

C. sake

2(0.1)

0-0.5

Unidentified C.

9 (0.6)

sp.
>1 C. spp.

51 (2.4)

Total

2089

'Ranges reflect data from all participating countries

2.3 C parapsilosis

C. parapsilosis is thought to be responsible for most candidaemia among neonates (Eggimann
et al, 2003). C parapsilosis is an exogenous pathogen, that may be found on skin as well as
on mucosal surfaces, which increases the potential for nosocomial spread by hand carriage
and introducing the pathogen to an already compromised host (Pfaller M.A. et al 2007).
Central venous catheters (CVCs) pose the greatest risk for C. Parapsilosis candidaemia
(Hachem et al, 2007). These devices support colonisation and biofilm formation, which
increases its drug resistance properties and protects the fungus from host defences
(Tumbarello M et al, 2007). CVCs are a significant risk for the development of candidaemia,
in patients without neutropenia or immunodeficiency, with half of BSIs acquired in the
intensive care unit being catheter related (Tumbarello M. et al, 2007). The high glucose media
via intravenous hyperalimentation nutrition also supports the ability of Candida parapsilosis
in colonisation of CVCs and the formation of biofilms (Tumbarello M. et al, 2007). The
formation of biofilms among C. albicans and C. parapsilosis isolates was shown to correlate
with increased mortality rates for patients, which suggests that the formation of such biofilms
may increase the pathogenicity of either/both of these strains (Tumbarello M. et al, 2007). In
the E.C.M.M. survey, a reduction in C. parapsilosis correlated with an increase in age (from
28-33% to 6.9%) (Tortorano M. et al, 2006).

2.4 C. trap kalis

C. tropicalis is associated with neutropenia. Interestingly, in three studies involving 369
strains in Asia C. tropicalis was the dominant strain at 43% compared to C. albicans at 34%,
and ranked second in Brazil at 25% following C. albicans at 34% (Eggiman et al, 2003).

2.5 C. krusei

C. glabrata and C. krusei were found in 31 and 24% of patients with haematological
malignancies as the leading cause of Candidaemia in a study of six hundred^and thirty five
patients (Hachem R. Et al, 2007). Fluconazole prophylaxis and neutropenia were identified as
risk factors (Hachem et al, 2007). In one study, C. krusei was found to occur most frequently
in patients with leukaemia and these patients had received fluconazole prophylaxis in 86% of
cases (Abbas J. Et al, 2001). C. krusei is associated with the highest rates of mortality among
the Candida species; this is partly due to its intrinsically resistant nature to the front line drug
of choice. Fluconazole.

3. Typing of Strains

Typing of Candida is important for epidemiological studies, it can dictate treatment choices
and give an indication of the morbidity and mortality associated with the infecting strain, as
well as providing data for prevention and control strategies. Most cases of candidaemia are
caused by a single Candida species; however infection with multiple species can also occur,
and these are more difficult to treat (Boktar et al, 2004). In routine hospital laboratories, there
is a reliance on phenotypic identification by methods including the germ tube test, CHROM
agar and the API 20C AUX sugar utilisation kit. Morphological differences including the
production of a germ tube is indicative of C. albicans, which can be diffrenciated from NAC
in this way. The API kit is not always exact and strains are sometimes misidentified by this
test (Yazbek J et al, 2007). These phenotypic tests are easy to perform, however they can be
time consuming and limiting, and the interpretation of results can be subjective. The potential
epidemiological shift away from C. albicans to NAC strains should highlight the importance
of correct strain identification. Phenotypic tests may not reflect true strain differences, so
molecular typing methods may be necessary.

Molecular typing methods include polymerase chain reaction (PCR) with capillary
electrophoresis (Turenne C.Y. et al, 1999), restriction fragment length polymorphism (RFLP)
(Williams D.W., et al, 2001) and single strand conformational polymorphism (SSCP) (Walsh
T.J. et al, 1995). The use of DNA Probes proved effective when discrepant results arose
during a surveillance study, between the referring laboratory and the Centre for Disease
Control and Prevention which identified C. glabrata as the most frequently misidentified
strain by phenotypic methods (Coignard C. et al, 2004). Real time PCR studies have allowed
the rapid detection of pathogenic fungi, by targeting the conserved 26S rDNA gene (Vollmer
T et al, 2008, Baskova L. Et al, 2007, Schabereiter et al, 2007). Sequencing of the D1/D2
region of the large subunit of the 26S rDNA gene can allow the differentiation of up to 500
yeast species (Kurtzman C.P. et al, 1998). Detection studies have also shown DNA
microarrays to be a promising diagnostic tool, in the identification of pathogenic fungi
(Leinberger et al, 2005, Speiss B. et al, 2007).

However, presently there is no one rapid, sensitive, easy to perform and inexpensive method
used in typing Candida, which is currently available to be microbiologist. Metwally et al

descride a real time PCR method, which rapidly differentiates between fluconazole-sensitive
and resistant species of Candida , directly from positive blood culture (Metally L. Et al,
2007). This method identifies the six most common clinical isolates and may be practical and
beneficial, in determining the most appropriate antifungal therapy, and could potentially
reduce the mortality associated with the use of fluconazole in resistant strains. Changing
epidemiological patterns highlight the need for improvement in diagnostic tests, with stain
identification as a necessary prerequisite in choosing the best candidate for antifungal therapy.

4. Drug Mechanism and Susceptibility
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Figure 2: Resistance to Fluconazole (Adapted from www.HIVwebstudv.oro)

Fluconazole inhibits the biosynthesis of ergosterol, found in the fungal cell wall, which is
absent in the mammalian cell (Hiller D. et al, 2006). Fluconazole is used as a first line defence
against systemic Candida infections, as it has a favourable adverse-effect profile (Metwally L
et al, 2007). Fluconazole is usually the drug of choice both prophylactically and with
suspected candidaemia. However the infecting strain will often determine the drug of choice,
as for e.g. if C. krusei is identified amphothericin B is a likely candidate for treatment. A
surveillance study at the Anderson Cancer Centre indicated that in cases of fluconazole
prophylaxis, C. glabrata and C. krusei dominated and in cases without fluconazole
prophylaxis that C. albicans dominated (Hache R. Et al, 2008). Other studies found no
correlation between fluconazole prophylaxis and an increase in the prevalence of C. glabrata
and C. krusei (Lin M. et al, 2005).
Antifungal resistance can be measured in vitro via its minimum inhibitory concentration
(MIC). According to the NCCLS (US National Committee for Clinical Laboratory
Standards), a susceptible isolate to fluconazole is indicated by MICs of 8.0 ug mL-1 or less.
10

and resistance at 64 ug mL-1 and values between these breakpoints are described as
‘susceptible, dose-dependent’ (SDD) (Sanglard D. Et al, 2002). Some studies have shown
strong correlation between MICs and clinical response, whereas others have had to reduce the
NCCLS recommendations for near perfect correlations (Sangland et al, 2002). Resistance in
vitro and clinical resistance to treatment in vivo do not always correlate, for several reasons
including, the patient’s immune system which is unaccounted for in vitro, if the antifungal
agent reaches the infection site in the right quantity and its interaction with other molecules at
the infection site (Sangland et al, 2002).

Resistance can be intrinsic i.e. prior to drug exposure or acquired post antifungal treatment
(Sanglard et al, 2002). Mechanisms of antifungal resistance include upregulation of the ATPbinding cassette (ABC) transporter efflux genes, amino acid substitutions in Ergl 1 or
upregulation of Ergl 1 and alterations in the ergosterol biosynthesis pathway (Sanglard et al,
2002). Upregulation of efflux pumps including CDRl, CDR2 and MDRl is one mechanism
of resistance, in which the drug is pumped out of the cell as quick as it enters and therefore
has no effect on the cell.

Table 6: Geographic variation in the in vitro susceptibilities of C. albicans, C. glabrata, and
C. tropicalis to fluconazole (Adapted from Pfaller et al, 2007, Artemis Surveillance
Programme).
Region

%R

%
R

3,368

13.5

3,120

8.1

1.2

8,642

16.0

3,930

2.6

4,566

0.6

564

19.1

350

2.9

Fluconazole

10,288

2.4

1,472

14.0

2,525

3.0

Fluconazole

4,644

5.1

2,106

20.5

740

3.6

%
R

No. of
isolates
tested

Fluconazole

18,125

0.9

Fluconazole

52,127

Fluconazole

Europe

Latin America

North America

C. tropicalis

No. of
isolates
tested

No. of
isolates
tested

Asia-Pacific

Africa/Middle
East

C. glabrata

C. albicans
Antifungal
agent
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Table 6, shows C. glabrata as the most likely isoh to be resistance to fluconazole,
compared to C. albicans and C. tropicalis in all geogracal regions. North America is the
region with the greatest resistance among C. albicans i C. glabrata isolates. The AsiaPacific region has the greatest resistance among C. trap/is, with almost twofold or greater
difference when compared to other regions. C tropicalis quite prevalent in the Asia Pacific
region however it is also quite prevalent in Latin Americbut with a much lower percentage
resistance. The reasons for such a high level of resiste in the Asia Pacific region are
unknown and may suggest the overuse of fluconazole. Age caseload of 52,127 C. albicans
isolates in Europe were tested, with just 1.2% of these istant compared to 5.1% of 4,644
isolates in North America. This difference although only xulative, may suggest the overuse
of fluconazole in North America, attributing to the ddopment of resistance among C.

albicans isolates.
Studies conducted by the E.C.M.M. demonstrated ancreased resistance among NAC
compared to C. albicans to amphothericin B (0.41 conred to 3.04%), flucytosine (1.88
compared to 5.32%) and fluconazole (1.27 compared to .29%) respectively (Tortorano A,
et al, 2006). Susceptibility profiles of Candida isolates y, with approximately 75% of C

krusei, 35% of C. glabrata, and 10-25% of C. tropiis and C lusitaniae resistant to
Fluconazole (Krcmery et al, 2002). If resistance increaseien alternative antifungals may be
required, in the treatment of candidaemia. Micafungin iie only drug from a new class of
antifungals, the echinocandin, which reduces toxicity ile maintaining potent antifungal
activity and has been shown to be as effective as flucczole (Fritz J.M. et al, year). The
echinocandin class target an essential cell wall compoit, have a unique mechanism of
action and are most likely to be used as a second le defence in combination with
azoles/polyenes (Kauffman C.A. et al, 2008). An additio challenge in treatment is biofilm
production among Candida species, which is associated th higher incidences of mortality
among patients with candidaemia, possibly due to inadtate fungal therapy and failure to
clear the organism from the blood (Tumbarello et al, 20C However, the E.C.M.M. surveys
suggest that presently antifungal resistance overall is quitow (Tortorano A. et al, 2006).
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5. Surveillance, Prevention and Management tf Candidaemia
5.1 Surveillance

Surveillance of antimicrobial resistance is important g^bally, and ongoing monitoring and
data collection is necessary for treatment recommendati-ns, in guidelines and policy making
for appropriate antifungal therapy, and in the assessmemof the outcome of antifungal therapy
(Pfaller M.A. et al, 2000). The epidemiology of canddaemia can vary according to the
institution and the population studied (Riddell J. Et a 2008). Due to a lack of adequate
surveillance data, hospitalisation data is often used to estimate the burden of the diseases
which leads to underestimating the incidence of this csease (Wamock D.W. et al, 2007).
These infections are non-notifyable and therefore casesgo unreported, which contributes to
inaccurate records of true disease (Wamock D.W. e al, 2007). Nosocomial clusters of
candidaemia in the intensive care ward, can be responsihe for up to one-third of all cases and
small clusters are often not identified by hospital sureillance (Asmundsdottir L.R. et al,
2008). Increasingly candidaemia also occurs outside le hospital in health care settings,
including the patient’s own home and in the outpatient seting (Warnocjk et al, 2007).

5.2 Prevention and Management
I.C. still remains a difficult pathogen to diagnose, prever and treat (Pfaller M.A. et al, 2007).
Risk factors include colonisation by Candida, antib3tics, neutropenia, vascular access
surgical procedures, and longer ICU stay (Eggimann et i, 2003). Only 5-15% of patients are
colonised on admission to hospital, however this increass to 50-86% during prolonged ICU
stay, with 5-30% developing severe candidiasis (Eggimnn et al, 2003). Simple preventable
measures include highlighting infection control strategic such as hand washing, appropriate
use, placement, removal and care of CVCs, and efficien antimicrobial therapy (Pfaller M.A.
et al, 2007). The administration of an appropriate antifuigal agent as an early, pre-emptive or
prophylactic therapy should reduce the unacceptably hih occurrence of I.C. and associated
mortality (Pfaller M.A. et al, 2007). The delay in waiting blood culture results may
contribute to a delay in administration of the antifungal gent and therefore improvements in
diagnostic, preventative and therapeutic strategies is neccsary (Pfaller M.A. et al, 2007).
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Inadequate and delayed antifungal therapy is associatec with increased risk of candidaemia
associated mortality (Tumbarello M. et al, 2007). Blocd cultures and sepsis symptoms are
non-specific and may only indicate candidiasis late ii infection (Eggimann et al, 2003).
Molecular methods including microarrays, may allow nore accurate and time saving results
allowing for the quicker administration of the appropriah anti-fungal agent. The emergence of
resistance to antifungals currently used, may see a mo^e towards a combination of old and
new antifungals including the echinocandins serving as scond line agents (Kauffman C.A. et
al, 2008).

6. Aims of Research
The aim of this study is to provide an epidemiologica snapshot of Candida isolates from
immunocompromised patients of Cork hospitals, "his study will be compared to
epidemiological trends globally. The twenty-five Candila isolates will be identified using a
phenotypic (API 20 C AUX Kit) and molecular method LSU of 26S rDNA gene) of typing.
The sensitivity of the commonly used API kit in ideitification will be determined, with
molecular sequencing as the gold standard. Flucona:ole susceptibility profiles will be
assigned to each isolate using the E-Test method and this will determine if drug resistance is a
problem in Cork hospitals
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Materials and Methods
Clinical Isolates
A total of twenty-five Candida isolates were included in this study from oncology, intensive
care units and infected catheters. Fifteen were obtained from the Microbiology Department of
Cork University Hospital (1-15) and nine from the Microbiology Department of the Bons
Secours Hospital Cork (16-24). One additional isolate was received from the Microbiology
Department U.C.C., which was also a clinical isolate (C.S. 25).

API 20C AUX Kit used in identiftcation of Candida spp.
The API 20C AUX kit was used according to the manufacturer’s guidelines (Biomerieux),
and the results were read after incubation at 30° C at 48 and for a last time at 72 hours. The
presence of turbidity in a well compared to the control well signified assimilation of that sugar
by the Candida species. Different Candida species will assimilate different sugars, and they
can be differentiated in this way. The germ tube test was also performed, in which a yeast
colony was emulsified in 0.5 ml of horse serum and incubated at 37° C for 3 hours. A drop
was then examined microscopically to confirm the presence or absence of germ tubes. A
positive test indicates Candida albicans and a negative test indicated Candida spp.

The

results were then input into an API Candida database.

KWH.'* V

.?swn«e.

if****-

Figure 3: API Test Kit.
Amplification of the DI/D2 domain of the 26S LSU rDNA gene

Fig ure 4: The D1/D2 region of the large subunit (LSU) of the 26S rDNA gene.
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Table 7: Primers used in amplification of the 26S LSU rDNA gene.

Primers

Sequence(5’-3’)

Function

NL-1

GCATATCAAGCGGAGGAAA

Amplification of the D1/D2 domain at the 5’
end of the LSU rDNA

NL-4

GGTCCGTGTTTCAAGACGG

Amplification of the D1/D2 domain at the 5’
end of the LSU rDNA

NL-2A

CTTGTTCGCTATCGGTCTC

Internal primer of NL-1

NL-3A

GAGACCGATAGCGAACAAG

Internal primer of NL-4

Figure 5: Map of primers bound to the nucleotide sequence of the D1/D2 domain of the
26S LSU rDNA gene.
NL4

801
CCCAAACACTCGCATAGACGTTAGACTCCTTGGTCCGTGTTICAACACGG (NL4)
851 GCGGCATATAACCATTATGCCAGCATCCTTGACTTACGTCGCAGTCCTCA
901 GTCCCAGCTGGCAGTATTCCCACAGGCTATAATACTTACCGAGGCAAGCT
951 ACATTCCTATGGATTTATCCTGCCACCAAAACTGATGCTGGCCCAGTGAA
1001 ATGCGAGATTCCCCTACCCACAAGGAGCAGAGGGCACAAAACACCATGTC
1051 TGATCAAATGCCCTTCCCTTTCAACAATTTCACGTACTTTTTCACTCTCT
1101

-----►

TTTCAAAGTTCTTTTCATCTTTCCATCACTGTAC rT(;T rC G( 1 ATC GGT(
1151
◄-----

NL2A
NL3A

ktcgccaatatttagctttagatggaatttaccacccacttagagctgc

1201 ATTCCCAAACAACTCGACTCTTCGAAGGCACTTTACAAAGAACCGCACTC
1251 CTCGCCACACGGGATTCTCACCCTCTATGACGTCCTGTTCCAAGGAACAT
1301 AGACAAGGAACGGCCCCAAAGTTGCCCTCTCCAAATTACAACTCGGGCAC
1351 CGAAGGTACCAGATTTCAAATTTGAGCTTTTGCCGCTTCACTCGCCGTTA
1401
CTAAGGCAATCCCGGTTGGTTTC TTTTC C TCCGC TTATTGATATGt TTAA (NLl)

NLl

Nucleotide variations in the conserved 26S rDNA gene are sufficient to differentiate up to 500
yeast species (Kurtzman et al, 1998). Primers NLl and NL2|.were used to amplify the 600 bp
region of the 26S LSU rDNA gene. DNA from the first PCR reaction, was used as a template
for the second PCR reaction, using primers (NLl and NL2A) and (NL3A and NL4). Each
PCR Reaction (50 ul) consisted of 25 ul of Master Mix (Go Taq Reaction Buffer (pH 8.5),
400 uM dATP, 400 uM dGTP, 400 uM dCTP, 400 uM dTTP, and 3 Mm MgCl), 2.5 ul of
each primer, 20 ul of water and either one colony for the initial PCR (of the 600 bp region), or
2 ug/0.2 ul of the first PCR Reaction for the second PCR Reaction (300 bp regions). The
following conditions were used for PCR amplification for the 600 and 300 bp regions: 96°C
for 4:00 mins, 94°C for 0:30 mins, 52°C for 0:30mins, 72°C for 4:20, and steps 2-4 were
repeated for 29 cycles. This was followed by 72°C for 10 mins.
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Agarose Gel Electrophoresis
PCR products were allowed to separate according to size on a 1% polyacrylamide gel, and
bands were visualised with ethidium bromide. Samples were allowed to run for approximately
30 minutes at 60-80 Volts. A 1Kb DNA ladder and molecular weight ladder VIII (Roche)
were used as markers to determine the band size of samples.

Purification of DNA and Sequencing
A QIA Purification Kit was used to purify DNA from the PCR sample, according to the
manufacturer’s protocol. Purified DNA (30 ul) was sent to GATC for sequencing. The
nucleotide sequence of each strain was then input into a web based search engine ‘blast’,
which gave the highest percentage of highly similar nucleotides, to that sequence, and the

Candida species was assigned to each isolate in this way, for the 600 and 300 bp regions of
each isolate.

Susceptibility Testing
Susceptibility of isolates to Fluconazole was determined using the E-Test method (AB
Biodisk, Solna, Sweden) and RPMl 1640 agar. E-Test strips contained fluconazole (0.016 to
256ug mL-1). The RPMI 1640 agar surface was inoculated by using a sterile swab dipped in a
cell suspension, and was allowed to dry for at least 15 minutes, the E-Test was then applied to
each plate. The plates were incubation at 37°C for 48 hrs. The MIC of all isolates were read at
the lowest concentration, at which the border of the elliptical inhibition zone intercepted the
scale on the strip. E-Test MlCs were read at 24 and 48 hours. Interpretive criteria for
susceptibility to fluconazole were used published by the NCCLS.
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Results
API Test Results - Phenotypic identification of Candida spp.
To determine the identity of each of the 25 Candida isolates, an API Kit was used. The
percentage match for all API test results, ranged from 93-99.9% maximum identity, apart
from sample no. 19, identified as C. famata, which had a value of just 88.1%. The most
prevalent strain was identified as C. albicans in 17/25 or 68% of isolates. C. parapsilosis was
the second most prevalent strain identified in 4/24 or 16% of isolates. C. glabrata, C. famata,
C. lusitaniae and C. dubliniensis were each present singly, representing 4% of the total
isolates each.

Table 8: API Test Results of 25 Candida isolates. (?) =Difficult to confirm the presence or
absence of germ tubes.
API 20 C AUX

Identification

% Match

1

6576174

C. albicans

98.5

2

6576174

C. albicans

98.5

3

6576174

C. albicans

98.5

4

6576174

C. albicans

98.5

5

6576174

C. albicans

98.5

6

6576174

C. albicans

98.5

7

6576174

C. albicans

98.5

8

6576131

C. parapsilosis

99.5

9

657617?

C. albicans

93.6

10

257617?

C. albicans

99.1

11

6576131

C. parapsilosis

99.5

12

6576131

C. parapsilosis

99.9

13

655237?

C. lusitaniae

94.8

14

257617?

C. albicans

99.1

15

657617?

C. albicans

93.6

16

2000040

C. glabrata

99.9

17

2576174

C. albicans

99.5

18

2576174

C. albicans

99.5

19

2556771

C. famata

88.1

20

2576174

C. albicans

99.5

21

2576174

C. albicans

99.5

22

2576174

C. albicans

99.5

23

6756134

C. parapsilosis

99.1

24

2576174

C. albicans

99.5

25

6172130

C. dubliniensis

93.0

Sample No.
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Sequencing - Molecular Identification of Candida spp.

The molecular approach to strain identification, involved PCR of the 26S LSU rDNA gene,
purification of the resulting DNA and sequencing to differentiate strains. Firstly, colony PCR
(with primers NLl and NL4) amplified a 600 bp region visualised by agarose gel
electrophoresis for samples 1-25, sho\\Ti in Figure 3, with a 1Kb ladder used as a marker.
DNA from the first PCR reaction was then used in a second PCR reaction (with primers NLl
and NL2A) and (NL4 and NL3A), to generate two 300bp regions, shown in Figures 6, 7 and
8, for samples 1-24.

Both 600 and 300 bp regions were amplified and sequenced as a shorter sequence of DNA
(300 bp rather than 600 bp) may yield a greater quality of read, and would reduce the chance
of hybridization to another region of the DNA. However, a ‘blast’ search of the nucleotide
sequence identified that the 300 and 600 bp regions matched in strain identity in all cases.
Sample no. 25 was received at a later date when all 600 bp regions were shown to match that
of the 300 bp regions, so only the 600 bp region was sequenced as this was sufficient to
resolve the identity of the Candida isolate.

600 bp

L 1 2

3

4 L

L

5

6

7 8

9 10 1 1 12 13 14 15 16 17 18 L 19 20 21 22 23 24 25 L

Figure 6: 600bp region of the 28S rDNA gene, of samples 1-25. L=lKb DNA Ladder.
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Figure 7: 300bp regions of samples 1-24, right panel is amplified by primers NLl and NL2A,
and left hand panel is amplified by NL4 and NL3A.
The extra bands visible for samples (1-9, and 11-12) were as a result of an excess of template
DNA (2 ul) when this was reduced 10 fold to 0.2 ul, just one band at 300 bp was visible

(10,

13-24)

Sequencing - DNA Blueprint in Fungal Identification

Following sequencing, and a blast search of each of the 600 and 300 bp regions, the strain of
each sample could be identified, as shown in Figure 8, which shows the steps in molecular
identification of sample no. 19, the one discrepant case between the two methods, correctly
identified as C. tropicalis, rather than C.famata by sequencing.
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AGCGGCGAGTGAAGCGGCAAAAGCTCAAATTTGAAATCTGGCTCTTTCAGAGTCCGAGTTGTAATT
TGAAGAAGGTATCTTTGGGTCTGGCTCTTGTCTATGTTTCTTGGAACAGAACGTCACAGAGGGTGA
GAATCCCGTGCGATGAGATGATCCAGGCCTATGTAAAGTTCCTTCGAAGAGTCGAGTTGTTTGGGA
ATGCAGCTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAAC
AAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAGAGTGAAAAAGTACGTGAAATTGTTG
AAAGGGAAGGGCTTGAGATCAGACTTGGTATTTTGTATGTTACTTCTTCGGGGGTGGCCTCTACAG
TTTATCGGGCCAGCATCAGTTTGGGCGGTAGGAGAATTGCGTTGGAATGTGGCACGGCTTCGGTTG
TGTGTTATAGCCTTCGTCGATACTGCCAGCCTAGACTGAGGACTGCGGTTTATACCTAGGATGTTGG
CATAATGATCTTAAGTCGCCCGTCT
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Figure 8: A) 600 bp nucleotide sequence for sample no. 19 B) Results of a ‘blast’ search of
this sequence showing 100% maximum identity to C. tropicalis C) Details of the strain and
organism.
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APIs - 96% Sensitivity when compared to Sequencing
Table 9: API vs. Sequencing Results.
Sample l.D.

API Result

Sequencing Result

1

C albicans

C. albicans

2

C. albicans

C. albicans

3

C. albicans

C. albicans

4

C. albicans

C. albicans

5

C. albicans

C. albicans

6

C. albicans

C. albicans

7

C. albicans

C. albicans

8

C. parapsilusis

C. parapsilosis

9

C. albicans

C. albicans

10

C. albicans

C. albicans

11

C. parapsilosis

C. parapsilosis

12

C. parapsilosis

C. parapsilosis

13

C. lusitaniae

C. lusitanaie

14

C. albicans

C. albicans

15

C. albicans

C. albicans

16

C. glabrata

C. glabrata

17

C. albicans

C. albicans

18

C. albicans

C. albicans

19

C. famata

C. tropicalis

20

C. albicans

C. albicans

21

C. albicans

C. albicans

22

C. albicans

C. albicans

23

C. parapsilosis

C. parapsilosis

24

C. albicans

C. albicans

25

C. dnbliniensis

C. dnbliniensis
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The API results matched the sequencing results in all cases, apart from sample no. 19 which
was identified as C. famata by the API method and C. tropicalis by sequencing, as shown in
Table 9. The API Test is 96% sensitive when compared to sequencing.

Fluconazole resistance is not apparent in Candida isolates from Cork hospitals
Figure 9: MICs of C. albicans isolates to Fluconazole.
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Susceptibility to fluconazole was determined, as it is used as a front line drug in the treatment
of candidiasis, and is also given as a preventative measure to patients prophylactically. To
investigate if resistance to this antifungal agent is a problem in Cork hospitals, susceptibility
profiles for each of the 25 isolates were determined with the E-Test. The results indicate that
all of the Candida spp were susceptible to Fluconazole, shown in figures 9 and 10, which
according to the NCCLS is a MIC of less than 8ug mL-1. The range of MICs for the C.
albicans strains was from 0.125-0.50 ug mL-1. The average MIC for the 17 C. albicans and 8
NAC isolates were 0.19ug mL-1 and 1.24 ug mL-1, respectively. The average MICs for the
NAC was 6.5 fold higher than for the C. albicans isolates.

Figure 10: A) C. parapsilosis isolates MIC varies from 0.19-2 ug Ml-1.
B) Other NAC isolates
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Discussion
This was a pilot study consisting of twenty-five Candida isolates, and the results generated
give an indication of the epidemiological profile in Cork, which can be compared to other
studies in Europe and globally. The Candida isolates were sourced from oncology, intensive
care units and infected catheters and did not include typical Candida infections from mucosal
isolates. It is the first lab based epidemiological study of Candida infections, in the
immunocompromised population in Ireland to date. Local epidemiological data of these life
threatening infections is important, for reasons such as a changing epidemiological trend and
the potential emergence of strains, with an increased resistance to common antifungal drugs.
This data could be used as a valuable tool, used to guide treatment choices and to support
changes in policy if necessary, such as catheter care and infection control practices.

The API kit is used routinely in hospital laboratories, for the identification of Candida
infections, it is easy to use, however it can be time consuming (48 hours) and the results can
be subjective. In this study, its sensitivity was compared to sequencing, which is the DNA
blueprint of the organism, and is therefore the definitive result. The API and sequencing
results matched in 24/25 cases, giving the API a 96% sensitivity when compared to the gold
standard. This shows the API kit to be a reliable and sensitive diagnostic test, suitable for the
identification of Candida infections in most cases. It is ideal for use in the hospital lab with
minimal labour and cost effectiveness, compared to molecular PCR and sequencing
identification. The one discrepant case, gave a much lower percentage maximum identity at
88.1% compared to all other results which were in the 93-99% range. This indicates that if a
lower API result is generated, perhaps less than 90% , then it may not be the actual identity of
the strain, and a molecular rather than phenotypic method may be necessary in these cases.
Studies have suggested an increase in the prevalence of NAC and a likewise decrease in C.
albicans (Pfaller et al, 2007). In this scenario, there will be increased pressure for correct
strain identification, due to greater mortality and drug resistance associated with NAC.
Presently, there is a lack of molecular diagnostic tests in use in clinical settings, however
several studies including the use of microarrays, have shown to be effective and may be
promising tools in the future (Leinberger et al, 2005, Speiss B. et al, 2007).
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Se'^eral studies have used the 26S rDNA gene for strain identification, in which nucleotide
vanations in this region, are sufficient to resolve individual yeast species (Vollmer T et al,
2008, Baskova L et al, 2007). Similarly, in this study, sequencing of the 26S rDNA gene was
used as a molecular method in strain identification, and is the gold standard. Sequencing
ideitified the true identity of one of the samples as C. tropicalis, rather than its API identity
as 7. famata. Sequencing, although more labour intensive and time consuming is required, if
the highest level of sensitivity in strain identification is required. For each sample, a large 600
bp region and two smaller 300 bp regions (of the 600 bp region) were amplified and sent off
for sequencing. In all cases, the two 300 bp regions matched the 600 bp region in strain
ideitification, giving confidence to the results. The potential for a mixed sample and also
po;sible hybridization to another region within the 600 bp region, were factors considered
whin the 300bp regions were included to be sequenced. However, the results indicated that
the;e factors didn’t materialise as a problem. This means that sequencing of the 600bp region
aloie, was sufficient to resolve yeast species, and gives the same quality read as the smaller
30( bp region.

In his study, sequencing identified the epidemiological profiles of isolates in Cork hospitals
as >8% (17/25) C. albicans, 16% (4/25) C parapsilosis, and 4% (1/25) each of C glabrata,
C. Popicalis, C. lusitaniae and C dubliniensis. C. albicans was the most prevalent strain
ideitified, consistent with other global studies including the ECMM, Sentry and the Artemis
Diik Surveillance Programme (Pfaller et al, 2001, Pfaller et al 2007, Tortorano, 2006). C.
panpsilosis was the second most common identified strain at 16%, this is consistent with
fmcings from the SENTRY programme which also found C. parapsilosis as the second most
doninant strain in Canada (16%), Latin America (25%), and Europe (19%) (Table 4, Pfaller
et d, 2001). The high prevalence of C. parapsilosis in Cork hospitals is worrying, as it is
assiciated with breaches in catheter care and in infection control practice, which suggests
the;e cases, may have been preventable. The advent of MRSA has highlighted the
reqiirement for stringent infection control practices, and results from this study, suggest that
furher education and changes in practices may be necessary.

In 1 more recent study by the ECMM of seven European countries, C. parapsilosis was the
thid most common isolate (13.3%), just marginally to C. glabrata (13.6%) (Tortorano, 2006).
Sinilarly in 19 studies of 5194 strains C. glabrata was the second most common strain (10%)
folbwed closely by C. parapsilosis (9%) (Eggimann et al, 2003). In the U.S. several studies
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have shown a vast increase in C. glabrata, possibly related to the use of low doses of the
common antifungal agent fluconazole. The most surprising data from this study was the low
prevalence of C glabrata, at just 4% of cases, unlike other European studies in which its
prevalence is similar or slightly greater than C. parapsilosis. This may suggest that Ireland is
lagging behind in this epidemiological shift, and may still potentially experience an upwards
trend in C. glabrata similar to that of C. parapsilosis. The patient population from which the
strains were isolated could also influence the results, with studies suggesting the occurrence
of NAC as more frequent (40-70%) in haematological malignancies and bone marrow
transplant recipients (Krcmery et al, 2002). A third reason, may be treatment choices in Cork,
with low dosage >400 of fluconazole suggested as a reason for the emergence of C. glabrata
in the U.S.

C. tropicalis was present at 4%, at a slightly lower prevalence than that found by the ECMM
study (7.2%) (Table 5, Tortorano, 2006), the Sentry Programme (7%) (Table 4, Pfaller, 2001)
and studies by the ARTEMIS DISK Surveillance Programme (7.5%) (Table 1, Pfaller, 2007).
It is associated in particular with neutropenia C lusitaniae and C. dubliniensis were each
present as one isolate, or at 4% of total isolates. Their presence suggest that more rare
Candida clinical isolates may be on the increase as descried also by the ARTEMIS DISK
Surveillance Programme (Table 1, Pfaller et al, 2007). Although C. albicans remains the
predominant clinical isolate, diverse ranges of NAC were present in this study. This means
there is a potential for NAC to emerge in Ireland in the future.

Susceptibility profiles for each isolate were determined by the E-Test method to fluconazole.
Each of the 25 isolates were susceptible, with MICs of less than 8ug Ml-1. This suggests that
resistance to Fluconazole is not a problem in Cork hospitals, as a resistant isolate has a MIC
of 64 ug mL-I. In general, the C. albicans isolates were much more susceptible compared to
the NAC with average MICs of 0.19ug/ml and I.24ug/ml respectively. The NAC had an
average 6.5 fold higher MIC values than the average values for the C. albicans isolates.
Studies by the ECMM have also found increased resistance among NAC at 10.29% of isolates
when compared to C. albicans at just 1.27% (Tortorano et al, 2006). There was also a ten fold
difference in MIC among C. parapsilosis isolates, between the most susceptible (0.19 ug mL1) and the more resistant isolates (2 ug mL-1). It would be interesting to determine reasons for
the differences in resistance among isolates, whether this is due to the over expression of
efflux pumps including MDRl, CDRl or CDR2 or for another reason including alterations in
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ergesterol biosynthesis. One method of determining whether overexpression of efflux pumps
has contributed to increased resistance among some isolates may be via reverse- transcription
PCR in which gene expression could be measured. There is a fivefold and a tenfold difference
in the MIC between the most susceptible and resistant isolate of C albicans and NAC isolates
respectively. These results suggest that whether a C. albicans or NAC strain is identified, will
determine to an extent if the isolate is more/less likely to be drug resistant. C. glabrata often
has higher levels of resistance to fluconazole, however in this case it was susceptible with a
MIC of 2ug mL-1.

In conclusion, this study is a snapshot of clinical isolates of Candida, present in the
immunocompromised population of Cork hospitals. A range of NAC were identified, which
means there is a potential for NAC to emerge, and therefore the need for further
epidemiological studies, to keep a watchful eye on a potential shifting trend, as seen globally.
C. parapsilosis was the most prevalent NAC present, highlighting the inadequacy in infection
control practices, in our hospitals. The API kit is a reliable and sensitive diagnostic test,
suitable for its role in the clinical setting. However, in the case of a changing epidemiological
trend, from C. albicans to NAC, then phenotypic identification may not suffice and
identification at the molecular level may be necessary. Molecular tests such as sequencing
may need to be employed if 100% accuracy is required. Drug resistance to fluconazole does
not appear to be an issue, which is positive for Cork hospitals. As expected, NAC had greater
levels of resistance compared to C. albicans isolates, and if there is a shift towards NAC then
greater levels of resistance should become more apparent.
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Appendix

Abbreviations
NAC

^on-albicans Candida

D1/D2

Domains 1 and 2

MIC

Minimum Inhibitory Concentration

HAART

Highly Active Antiretroviral Therapy

ECMM

European Confederation of Medical Mycology

1C

Invasive Candidiasis

PCR

Polymerase Chain Reaction

RFLP

Restriction Fragment Length Polymorphism

SSCP

Single Strand Conformational Polymorphism

rDNA

Ribosomal DNA

NCCLS

National Committee for Clinical Laboratory Standards

LSU

Large Subunit
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